Rallybio (RLYB) Change in Account Payables (2020 - 2026)
Rallybio (RLYB) posted Change in Account Payables of $814000.0 for Q1 2026, up 669.23% sequentially from -$143000.0 in Q4 2025, and up 567.21% YoY from $122000.0 in Q1 2025.
Rallybio (RLYB) Change in Account Payables (2020 - 2026) Analysis & Trends
Rallybio has reported Change in Account Payables for 7 years, with the latest figure at $814000.0 in Q1 2026.
- Quarterly Change in Account Payables rose 567.21% year-over-year to $814000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $540000.0 (up 871.43% YoY) and the FY2025 annual result came in at -$152000.0, up 78.22% from the prior year.
- Change in Account Payables improved to $814000.0 in Q1 2026 per RLYB's latest filing, from -$143000.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $814000.0 in Q1 2026 and troughed at -$635000.0 in Q3 2024.
- A 5-year average of $20705.9 and a median of -$92000.0 in 2023 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2023 and 2024: Change in Account Payables tumbled 427.78% in 2023, then soared 913.04% in 2024.
- Over 5 years, Change in Account Payables stood at $392000.0 in 2022, then soared by 33.67% to $524000.0 in 2023, then sank by 158.21% to -$305000.0 in 2024, then jumped by 53.11% to -$143000.0 in 2025, then surged by 669.23% to $814000.0 in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered $814000.0, -$143000.0, and $150000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Rallybio | 94.61 Mn | 94.61 Mn | - | -107,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -107,000.00 |
| Jun 30, 2026 | -107,000.00 |
| Mar 31, 2026 | 814,000.00 |
| Mar 31, 2026 | 814,000.00 |
| Dec 31, 2025 | -143,000.00 |
| Dec 31, 2025 | -143,000.00 |
| Sep 30, 2025 | 150,000.00 |
| Sep 30, 2025 | 150,000.00 |
| Jun 30, 2025 | -281,000.00 |
| Jun 30, 2025 | -281,000.00 |
| Mar 31, 2025 | 122,000.00 |
| Mar 31, 2025 | 122,000.00 |
| Dec 31, 2024 | -305,000.00 |
| Dec 31, 2024 | -305,000.00 |
| Sep 30, 2024 | -635,000.00 |
| Sep 30, 2024 | -635,000.00 |
| Jun 30, 2024 | 748,000.00 |
| Jun 30, 2024 | 748,000.00 |
| Mar 31, 2024 | -506,000.00 |
| Mar 31, 2024 | -506,000.00 |